Immutep Limited ADR (IMMP) Implied Volatility Current

Tracking IMMP implied volatility helps you identify when options premiums on Immutep Limited ADR are historically cheap or expensive, and where the best trades are hiding. Immutep Limited ADR implied volatility reflects the market's expectation of future price movement: when IMMP IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Immutep Limited ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For IMMP, tracking metrics like IMMP IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on IMMP signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors.

Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where IMMP implied volatility sits today versus where it has been. Our scanner ranks Immutep Limited ADR implied volatility against its historical range, surfaces extremes in IMMP IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Immutep Limited ADR IV is rich or cheap — measure it, then act on it.